Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fast As A Whip, Pfizer Files Personalized Lung Cancer Drug Crizotinib

This article was originally published in The Pink Sheet Daily

Executive Summary

One of three Pfizer cancer drugs to be filed in 2011, crizotinib may help to turn the tide on pipeline setbacks. Axitinib and bosutinib filings are still to come.
Advertisement

Related Content

Team Work: Pfizer, Abbott Gain Swift Approvals For Lung Cancer Drug/Test Combo
Pfizer’s Crizotinib Eases Past FDA With Targeted Population
Pfizer's Crizotinib Eases Past FDA With Targeted Population
Survival Data For Pfizer's Crizotinib Appears Promising, Positioning It For Accelerated Approval
Companion Diagnostics: A Business Area Fraught With Challenges Ahead
Targeted Oncologics ISO Companion Diagnostics To Find Attractive Patients
Targeted Oncologics ISO Companion Diagnostics To Find Attractive Patients
Avastin's Next Stop May Be Hearing As FDA Starts Withdrawal Process For Breast Cancer Claim
Mylotarg Pulled Off Market, But Pfizer Continues Search For Appropriate Population
Mylotarg Pulled Off Market, But Pfizer Continues Search For Appropriate Population

Topics

Advertisement
UsernamePublicRestriction

Register

PS071684

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel